Log in

Oxford BioMedica Stock Price, Forecast & Analysis (OTCMKTS:OXBDF)

$7.50
+0.30 (+4.09 %)
(As of 11/20/2019 04:03 AM ET)
Today's Range
$7.50
Now: $7.50
$7.50
50-Day Range
$6.20
MA: $6.94
$7.50
52-Week Range
$6.20
Now: $7.50
$10.02
Volume800 shs
Average Volume422 shs
Market Capitalization$492.60 million
P/E Ratio50.00
Dividend YieldN/A
Beta0.77
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments. Read More…

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:OXBDF
Previous SymbolNASDAQ:OXBDF
CUSIPN/A
CIKN/A
Phone44-18-6578-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$89.14 million

Profitability

Miscellaneous

Employees432
Market Cap$492.60 million
Next Earnings DateN/A
OptionableNot Optionable

Receive OXBDF News and Ratings via Email

Sign-up to receive the latest news and ratings for OXBDF and its competitors with MarketBeat's FREE daily newsletter.


Oxford BioMedica (OTCMKTS:OXBDF) Frequently Asked Questions

What is Oxford BioMedica's stock symbol?

Oxford BioMedica trades on the OTCMKTS under the ticker symbol "OXBDF."

What price target have analysts set for OXBDF?

1 analysts have issued 1 year price objectives for Oxford BioMedica's stock. Their forecasts range from $14.50 to $14.50. On average, they anticipate Oxford BioMedica's share price to reach $14.50 in the next twelve months. This suggests a possible upside of 93.3% from the stock's current price. View Analyst Price Targets for Oxford BioMedica.

What is the consensus analysts' recommendation for Oxford BioMedica?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford BioMedica in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford BioMedica.

What are Wall Street analysts saying about Oxford BioMedica stock?

Here are some recent quotes from research analysts about Oxford BioMedica stock:
  • 1. According to Zacks Investment Research, "Oxford BioMedica Plc is a gene and cell therapy company which focused on developing life changing treatments for serious diseases. Oxford BioMedica Plc is headquartered in Oxford, the United Kingdom. " (11/13/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and 1450p price target. Our price target is based on our clinical net present value (NPV) model, which derives value primarily from Novartis’ CTL019 (lentiviral production and royalty). This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (9/4/2019)

Has Oxford BioMedica been receiving favorable news coverage?

News headlines about OXBDF stock have been trending very negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oxford BioMedica earned a daily sentiment score of -3.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Oxford BioMedica.

Who are some of Oxford BioMedica's key competitors?

What other stocks do shareholders of Oxford BioMedica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford BioMedica investors own include Petra Diamonds (PDL), Oxford BioMedica (OXB), Ferrexpo (FXPO), Fresenius Medical Care AG & Co. KGaA (FME), Nokia Oyj (NOKIA), Hummingbird Resources (HUM), Royal Dutch Shell (RDSB), Lloyds Banking Group (LLOY), Rapid7 (RPD) and RWE (RWE).

Who are Oxford BioMedica's key executives?

Oxford BioMedica's management team includes the folowing people:
  • Mr. John Dawson, CEO & Exec. Director (Age 59)
  • Mr. Stuart Paynter, CFO & Director
  • Mr. Timothy William Watts, Exec. Officer (Age 61)
  • Mr. Peter Nolan, Consultant (Age 66)
  • Mr. Nick Page, Chief Operations Officer

How do I buy shares of Oxford BioMedica?

Shares of OXBDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Oxford BioMedica's stock price today?

One share of OXBDF stock can currently be purchased for approximately $7.50.

How big of a company is Oxford BioMedica?

Oxford BioMedica has a market capitalization of $492.60 million and generates $89.14 million in revenue each year. Oxford BioMedica employs 432 workers across the globe.View Additional Information About Oxford BioMedica.

What is Oxford BioMedica's official website?

The official website for Oxford BioMedica is http://www.oxfordbiomedica.co.uk/.

How can I contact Oxford BioMedica?

Oxford BioMedica's mailing address is Windrush Court Transport Way, Oxford X0, OX4 6LT. The company can be reached via phone at 44-18-6578-3000.


MarketBeat Community Rating for Oxford BioMedica (OTCMKTS OXBDF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Oxford BioMedica and other stocks. Vote "Outperform" if you believe OXBDF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXBDF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel